Feel free to use our complete database with charts, tables and examples.
Pantoprazole (Protonix ®) |
||||||||||||||||
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither NewMedicalTerms Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. | ||||||||||||||||
Usual Diluents |
||||||||||||||||
NS , D5W , LR | ||||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
||||||||||||||||
[40 mg] [100 ml] [15 minutes] 1. Reconstitute each vial of PROTONIX I.V. with 10 mL of 0.9% Sodium Chloride Injection, USP. 2. Combine the contents of the two vials and further dilute with 80 mL of 5% Dextrose Injection, USP, 0.9% Sodium Chloride Injection, USP, or Lactated Ringer's Injection, USP, to a total volume of 100 mL with a final concentration of approximately 0.8 mg/mL. 3. Inspect the diluted PROTONIX I.V. solution visually for particular matter and discoloration prior to and during administration. 4. Administer intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min. ---------------------------------- Minimum dilution: Diluted vial (4 mg/ml) can be administered over at least 2 minutes. Storage |
||||||||||||||||
Stability / Miscellaneous |
||||||||||||||||
Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome: PROTONIX I.V. for Injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions. Prevention of rebleeding in peptic ulcer bleed (unlabeled use): I.V.: 80 mg, followed by 8 mg/hour infusion for 72 hours. Note: A daily infusion of 40 mg does not raise gastric pH sufficiently to enhance coagulation in active GI bleeds. DOSAGE AND ADMINISTRATION Midazolam HCl has been shown to be incompatible with Y-site administration of PROTONIX I.V. for Injection. PROTONIX I.V. for Injection may not be compatible with products containing zinc. When PROTONIX I.V. for Injection is administered through a Y-site, immediately stop use if precipitation or discoloration occurs. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit. Treatment with PROTONIX I.V. for Injection should be discontinued as soon as the patient is able to be treated with PROTONIX Delayed-Release Tablets. Also, data on the safe and effective dosing for conditions other than those described in INDICATIONS AND USAGE, such as life-threatening upper gastrointestinal bleeds, are not available. PROTONIX I.V. 40 mg once daily does not raise gastric pH to levels sufficient to contribute to the treatment of such life-threatening conditions. Parenteral routes of administration other than intravenous are not recommended. No dosage adjustment is necessary in patients with renal impairment, hepatic impairment, or for elderly patients. Doses higher than 40 mg/day have not been studied in hepatically-impaired patients. No dosage adjustment is necessary in patients undergoing hemodialysis. Treatment of Gastroesophageal Reflux Disease Associated With a History of Erosive Esophagitis Fifteen Minute Infusion PROTONIX I.V. for Injection admixtures should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min. Two Minute Infusion Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome Fifteen Minute Infusion PROTONIX I.V. for Injection should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL/min. Two minute Infusion HOW SUPPLIED PROTONIX I.V. for Injection is available as follows: Storage Wyeth® Marketed by Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101 under license from Nycomed GmbH D78467 Konstanz, Germany W10447C017 ET01 Rev 12/07 Source: [package insert] |